During the past 10 years, high-dose chemotherapy (HDCT) has emerged as a fe
asible and curative treatment option for patients with multiply relapsed an
d/or refractory germ-cell tumors. increasing experience and the results fro
m clincial trials have helped to optimize the application of HDCT and to de
fine its role in the salvage concepts for germ-cell tumors. (C) 1999 Wiley-
Liss, Inc.